Clarence Runnels
Psychiatric/Mental Health · Creedmoor, NCNPI 1487129649
Payments from drug & device makers
Across 1,153 payments — averaging $294.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$194K
- Neurocrine Biosciences, Inc.$67K
- Axsome Therapeutics, Inc.$49K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$14K
- Alkermes, Inc.$6K
- Idorsia Pharmaceuticals US Inc$3K
- plus $5K from 19 others
What the payments were for
- Consulting fees$48,79014%
- Speaking & faculty fees$223,40266%
- Travel & lodging$47,39114%
- Food & beverage$19,3116%
- Education$2610%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 432 | $194,367 |
| Neurocrine Biosciences, Inc. | 126 | $67,359 |
| Axsome Therapeutics, Inc. | 104 | $48,659 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 91 | $14,363 |
| Alkermes, Inc. | 78 | $5,895 |
| Idorsia Pharmaceuticals US Inc | 23 | $3,451 |
| Supernus Pharmaceuticals, Inc. | 109 | $1,316 |
| Teva Pharmaceuticals USA, Inc. | 32 | $854 |
| Sunovion Pharmaceuticals Inc. | 32 | $481 |
| Lundbeck LLC | 23 | $427 |
| Otsuka America Pharmaceutical, Inc. | 17 | $373 |
| Takeda Pharmaceuticals U.S.A., Inc. | 13 | $239 |
| Johnson & Johnson | 12 | $220 |
| Vanda Pharmaceuticals Inc. | 11 | $200 |
| Neos Therapeutics, LP | 11 | $185 |
| Tris Pharma Inc | 9 | $154 |
| E.r. Squibb & Sons, L.L.C. | 3 | $151 |
| Corium, LLC | 7 | $132 |
| Bausch Health US, LLC | 6 | $121 |
| Almatica Pharma LLC | 6 | $94 |
| Ironshore Pharmaceuticals Inc. | 2 | $29 |
| Noven Therapeutics, LLC | 2 | $27 |
| Eisai Inc. | 2 | $25 |
| Janssen Scientific Affairs, LLC | 1 | $18 |
| Alfasigma USA, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$339,155 in reported general payments places this provider in the 95th percentile of 947 psychiatric/mental health providers in North Carolina.
See all psychiatric/mental health providers in North Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 32 | $260,921 |
| Austedo XrDeutetrabenazine | 11 | $56,365 |
| TrintellixVortioxetine Hydrobromide | 28 | $22,658 |
| AuvelityDextromethorphan Hbr/Bupropion | 15 | $19,810 |
| BelsomraSuvorexant | 21 | $10,795 |
| VyvanseLisdexamfetamine Dimesylate | 24 | $8,963 |
| Vilazodone Hcl | 67 | $7,278 |
| Lisdexamfetamine Dimesylate | 29 | $6,990 |
| Ramelteon | 19 | $5,621 |
| Lurasidone Hcl | 38 | $5,276 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 132 | $3,379 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 61 | $3,299 |
| Clonazepam | 309 | $3,118 |
| Aripiprazole | 65 | $2,941 |
| Bupropion XlBupropion Hcl | 119 | $2,837 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $67,359 | $260,92132 claims |
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $854 | $56,36511 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $239 | $31,62252 claims |
| Axsome Therapeutics, Inc.Auvelity | $48,659 | $19,81015 claims |
| Almatica Pharma LLCSertraline Hcl | $94 | $45738 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 947 psychiatric/mental health providers in North Carolina.
Other psychiatric/mental health in Creedmoor
- Benjamin MastridgeCreedmoor$8K
- Desiree MatthewsCharlotte$807K
- Benedetto PalomboCharlotte$671K
- Lisa SuddrethGastonia$111K
- April NandigamGreensboro$88K
- Hannah NealeyFuquay Varina$75K
- Jessica StoneRocky Mount$63K
- Deborah GranickRaleigh$28K
- Ronald PattersonFayetteville$25K
- Ajay PatelRaleigh$19K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.